<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03978949</url>
  </required_header>
  <id_info>
    <org_study_id>S2019-0657-0003</org_study_id>
    <nct_id>NCT03978949</nct_id>
  </id_info>
  <brief_title>Prevention of Radiotherapy Induced Enteropathy by Probiotics (PREP)</brief_title>
  <official_title>Prevention of Radiotherapy Induced Enteropathy by Probiotics (PREP Trial): a Prospective, Randomized Controlled, Double Blinded, Single Center, Superiority Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In recent studies, a radiation-induced enteropathy is being reported over 50%. In clinics,
      probiotics are actively prescribed as a treatment for radiation-induced enteropathy. If
      probiotics can be used during radiation therapy to prevent or reduce radiation-induced
      enteropathy, the investigators can 1) reduce the inconvenience which is caused from
      intestinal toxicity, 2) reduce the unnecessary interruption of radiation therapy, and 3)
      expect to improve the quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with grade 2 or more acute intestinal toxicities</measure>
    <time_frame>Adverse effect evaluated at 3 months after radiation therapy</time_frame>
    <description>Evaluation using CTCAE version 4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with grade 2 or more chronic intestinal toxicities</measure>
    <time_frame>Adverse effect occured after 3 months since end of radiation therapy</time_frame>
    <description>Evaluation using CTCAE version 4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">248</enrollment>
  <condition>Radiotherapy</condition>
  <condition>Toxicity</condition>
  <condition>Diarrhea</condition>
  <condition>Probiotics</condition>
  <arm_group>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two weeks prior to the start of radiation therapy, the probiotics is administered three times daily until the end of radiation therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two weeks prior to the start of radiation therapy, the placebo is administered three times daily until the end of radiation therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bacillus Licheniformis</intervention_name>
    <description>Two weeks prior to the start of radiation therapy, the probiotics is administered three times daily until the end of radiation therapy.</description>
    <arm_group_label>Probiotics</arm_group_label>
    <other_name>Biscanen cap.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two weeks prior to the start of radiation therapy, the placebo is administered three times daily until the end of radiation therapy.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo oral tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven uterine cancer, ovarian cancer, vaginal cancer, vulvar cancer,
             ureter cancer, kidney cancer, urethral cancer, and prostate cancer

          -  Over 20 years of age

          -  Eastern Cooperative Oncology Group (ECOG) score 0-2

          -  Appropriate values of blood test within 6 months after enrollment Absolute neutrophil
             count (ANC) ≥ 1500 cells/mm3, platelets≥50000cells/mm3

          -  Appropriate values of kidney function within 6 months after enrollment Creatinin &lt; 2.0
             ng/dL

          -  Appropriate values of liver function within 6 months after enrollment Total bilirubin
             &lt; 1.5 times upper limit normal range, alanine aminotransferase or aspartate
             aminotransferase &lt; 2.5 times upper limit normal range.

          -  Willing to provide informed written consent

        Exclusion Criteria:

          -  History of pelvic irradiation

          -  Double primary cancer other than skin/thyroid cancer

          -  Combined serious morbidity

          -  Experience of other clinical trial within 1 month.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Seok Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young Seok Kim, M.D., PhD.</last_name>
    <phone>82 2 3010 5614</phone>
    <phone_ext>5614</phone_ext>
    <email>ysk@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Seok Kim, M.D., Ph.D.</last_name>
      <phone>82 2 3010 5614</phone>
      <phone_ext>5614</phone_ext>
      <email>ysk@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Young Seok Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

